The difference in the CAIX plasma level may reflect distinct molecular pathways and genetic alterations that impact small-sized tumours, which may determine the subsequent development and risk of progression, as already suggested for bladder cancers (Turner et al, 2002). This evidence concerns the gene CA9 and urinary bladder cancer.